Abstract
Glaucoma and diabetic retinopathy (DR) are among the leading causes of blindness in the world1 and in China.2,3 Glaucoma was estimated to affect 60.5 million persons in 2010,4 and it seems that the prevalence of diabetes in the world's most populous countries is growing rapidly,5,6 likely an indication of a commensurate rise in associated eye disease. Glaucoma and DR have been included as targets for reduction in the burden of avoidable blindness by Global Vision 2020,7 and each has therapies that have been proved effective in large randomized controlled trials.8,9

This publication has 28 references indexed in Scilit: